XXXX metastatic to abdomen and pelvis: role of surgical resection.

@entity1 @entity1625 @entity0 @entity66 @entity3
OBJECTIVE: The purpose of this study was to describe the characteristics and outcome of @entity1 with metastatic @entity0 to the abdomen and pelvis, and to assess the role of surgical resection of abdominal and pelvic @entity3 in this disease. METHODS: We retrospectively reviewed the medical records of 59 @entity1 with documented metastatic @entity0 to the abdomen or pelvis who had exploratory surgery by the Gynecology Service between 1986 and 2001. RESULTS: Exploratory surgery was performed a median of 5 years (range, 0-25 years) after initial diagnosis of @entity0 . Median survival from diagnosis of @entity1625 was 23 months, and 5-year survival was 24%. Survival was 36 months for optimally debulked @entity1 (<2 cm of @entity66 ) and 20 months for suboptimally debulked @entity1 (P = 0.07). @entity1 diagnosed 5 or more years after initial @entity0 had a median survival of 36 months versus 17 months if diagnosed earlier (P < 0.01). On multivariate analysis the time to recurrence of @entity0 in the abdomen and optimal debulking were both significant variables. Hazard ratio for dying of disease if recurring before 5 years was 2.7 (CI 1.45-5.03) [P < 0.01]. Hazard ratio for dying of disease if suboptimal debulking was achieved was 2.14 (CI 1.13-4.02) [P = 0.02]. CONCLUSIONS: The disease pattern of metastatic @entity0 to the abdomen and pelvis does not appear to effect survival. Survival in @entity1 where optimal debulking is achieved and in those recurring late is improved. Surgical resection of metachronous metastatic @entity0 to the abdomen and pelvis may be an important component of the management of this disease and should be considered in candidate @entity1 .
